- GAAP Revenue of $16.5 Million, up
16%
- GAAP EPS of $0.19, Non-GAAP EPS of
$0.38
- Fiscal 2016 Guidance
Reaffirmed
SurModics, Inc. (NASDAQ:SRDX), a leading provider of medical
device and in vitro diagnostic technologies to the healthcare
industry, today announced results for its fiscal 2016 first
quarter, ended December 31, 2015.
“The SurModics team had an exceptional first quarter of fiscal
2016,” said Gary Maharaj, president and chief executive officer.
“We delivered outstanding results from our core Medical Device and
In Vitro Diagnostic businesses while completing both the November
2015 Creagh Medical and January 2016 NorMedix acquisitions. We are
well-positioned to meet our fiscal 2016 financial commitments with
our first quarter financial results as well as execute our future
growth with our whole products solutions strategy with these
acquisitions and our continued progress on the SurModics SurVeil TM
drug-coated balloon platform. ”
First Quarter Revenue and Earnings Summary
GAAP revenue for the fiscal 2016 first quarter totaled $16.5
million, compared with $14.2 million a year earlier. First quarter
fiscal 2016 revenue included $0.5 million from Creagh Medical.
Diluted GAAP earnings per share from continuing operations in
the first quarter of fiscal 2016 were $0.19 compared with $0.27 a
year ago. Both the first quarter of fiscal 2016 and 2015 earnings
include a $0.02 per share discrete income tax benefit from the
renewal of the federal research and development tax credit. As
indicated by SurModics earlier this month, fiscal 2016 first
quarter earnings also reflect a $0.20 per share reduction from
Creagh Medical acquisition-related transaction costs including
investment banker fees, integration, contingent consideration
accretion, foreign currency transaction and other expenses. On a
non-GAAP comparative basis, earnings per share were $0.38 in the
first quarter of fiscal 2016 versus $0.26 last year, an increase of
46%.
Medical Device Segment
This business, which includes hydrophilic coatings, device drug
delivery technologies, and balloon catheter products, posted
revenue of $12.2 million in the first quarter of fiscal 2016, an
increase of 15% compared to the year-ago period. The gain stems
from higher hydrophilic royalties, reagent product sales, and
research and development contract coating services as well as the
Creagh Medical acquisition. Fiscal first quarter 2016 hydrophilic
coating royalty revenue was $7.5 million, an increase of 6%
compared to the year-earlier period. The Medical Device business
unit generated $3.8 million of operating income in the first
quarter compared to $5.5 million in the prior-year quarter. Higher
gross margin from revenue gains was more than offset by $2.8
million of Creagh Medical transaction-related expenses,
amortization, accretion and foreign currency transaction loss
costs.
In Vitro Diagnostics Segment
Revenue for the first quarter of fiscal 2016 totaled $4.3
million, an increase of 20% compared to the year-ago period. The
IVD business unit generated $1.6 million of operating income in the
first quarter of fiscal 2016, which reflects a 50% increase
from a year ago. Operating income benefited from improved operating
leverage due to higher revenue and lower legal costs.
Balance Sheet and Cash Flow
As of December 31, 2015, the Company had $42.7 million of cash
and investments. SurModics generated cash from operating activities
of $6.1 million in the first quarter of fiscal 2016. Capital
expenditures totaled $0.4 million for the first quarter of fiscal
2016. In addition, the Company used $18.2 million of net cash to
acquire Creagh Medical in the first quarter.
Fiscal 2016 Outlook
SurModics is reaffirming its previously stated guidance for
fiscal 2016. The Company expects revenue to range from
$62 million to $66 million, with diluted GAAP earnings in the
range of $0.30 to $0.35 per share and non-GAAP earnings of $0.66 to
$0.75 per share.
Live Webcast
SurModics will host a webcast at 7:30 a.m. CT (8:30 a.m. ET)
today to discuss first quarter results. To access the webcast, go
to the investor relations portion of the Company’s website at
www.surmodics.com and click on the webcast icon. A replay of the
first quarter conference call will be available by dialing
888-203-1112 and entering conference call ID passcode 167645. The
audio replay will be available beginning at 10:30 a.m. CT on
Thursday, January 28, 2016, until 10:30 a.m. CT on
Thursday, February 4, 2016.
About SurModics SurVeil™ Drug-Coated Balloon
The SurVeil drug-coated balloon incorporates SurModics’ decades
of experience as a leading supplier of surface modification
technologies to the medical device industry. It includes a
SurModics-proprietary drug-excipient formulation for the balloon
coating, and a new and proprietary manufacturing process for the
coating applications. It also includes the SurModics Serene™
low-friction, low-particulate hydrophilic coating on the catheter
shaft. The SurVeil DCB is not available for sale in the US and is
for investigational use only. We plan to initiate a first-in-human
clinical trial using SurModics SurVeil drug-coated balloon by the
end of the second quarter of fiscal 2016.
About SurModics, Inc.
SurModics partners with the world’s leading and emerging medical
device, diagnostic and life science companies to develop and
commercialize innovative products designed to improve lives by
enabling the detection and treatment of disease. Our mission is to
be a trusted partner to our customers by providing the most
advanced surface modification technologies and in vitro diagnostic
chemical components that help enhance the well-being of patients.
The Company’s core offerings include surface modification coating
technologies that impart lubricity, prohealing, and
biocompatibility characteristics and components for in vitro
diagnostic test kits and microarrays. SurModics’ strategy is to
build on the product and technical leadership within these fields,
and expand the core offerings to generate opportunities for longer
term sustained growth. SurModics is headquartered in Eden Prairie,
Minnesota. For more information about the Company, visit
www.surmodics.com. The content of SurModics’ website is not part of
this press release or part of any filings that the Company makes
with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements.
Statements that are not historical or current facts, including
statements about beliefs and expectations regarding the Company’s
performance in the near- and long-term, including our revenue,
earnings and cash flow expectations for fiscal 2016, our fiscal
2016 priorities, and our SurVeil drug-coated balloon, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and important factors could cause
actual results to differ materially from those anticipated,
including (1) our ability to successfully develop, obtain
regulatory approval for, and commercialize our SurVeil drug-coated
balloon product, including the timing associated with the
initiation of our first-in-human clinical trial; (2) our reliance
on third parties (including our customers and licensees) and their
failure to successfully develop, obtain regulatory approval for,
market and sell products incorporating our technologies; (3) our
ability to successfully identify and acquire target companies or
achieve expected benefits from acquisitions that are consummated;
(4) possible adverse market conditions and possible adverse impacts
on our cash flows, and (5) the factors identified under “Risk
Factors” in Part I, Item 1A of our Annual Report on Form 10-K for
the fiscal year ended September 30, 2015, and updated in our
subsequent reports filed with the SEC. These reports are available
in the Investors section of our website at www.surmodics.com and at
the SEC website at www.sec.gov. Forward-looking statements speak
only as of the date they are made, and we undertake no obligation
to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with
generally accepted accounting principles, or GAAP, SurModics is
reporting non-GAAP financial results including non-GAAP operating
income, non-GAAP income before income taxes, non-GAAP net income,
and non-GAAP diluted net income per share. We believe that these
non-GAAP measures provide meaningful insight into our operating
performance excluding certain event-specific matters, and provide
an alternative perspective of our results of operations. We use
non-GAAP measures, including those set forth in this release, to
assess our operating performance and to determine payout under our
executive compensation programs. We believe that presentation of
certain non-GAAP measures allows investors to review our results of
operations from the same perspective as management and our board of
directors and facilitates comparisons of our current results of
operations. The method we use to produce non-GAAP results is not in
accordance with GAAP and may differ from the methods used by other
companies. Non-GAAP results should not be regarded as a substitute
for corresponding GAAP measures but instead should be utilized as a
supplemental measure of operating performance in evaluating our
business. Non-GAAP measures do have limitations in that they do not
reflect certain items that may have a material impact on our
reported financial results. As such, these non-GAAP measures should
be viewed in conjunction with both our financial statements
prepared in accordance with GAAP and the reconciliation of the
supplemental non-GAAP financial measures to the comparable GAAP
results provided for the specific periods presented, which are
attached to this release.
SurModics, Inc. and Subsidiaries Condensed
Consolidated Statements of Income
(in thousands, except per share data)
Three Months EndedDecember
31,
2015 2014
(Unaudited) Revenue Royalties and license fees $ 7,954 $ 7,275
Product sales 7,181 5,847 Research and development 1,406
1,083 Total revenue 16,541
14,205 Operating expenses Product costs 2,366
1,902 Research and development 3,634 3,576 Selling, general and
administrative 3,608 3,542 Amortization, special and other charges
2,994 151 Total operating costs and
expenses 12,602 9,171 Operating income
3,939 5,034 Other (loss) income, net (134 ) 50
Income before income taxes 3,805 5,084 Income tax
provision (1,292 ) (1,470 ) Net income $ 2,513
$ 3,614 Basic net income per share $ 0.19 $
0.27 Diluted net income per share $ 0.19 $
0.27 Weighted average shares outstanding Basic 12,966
13,225 Diluted 13,186 13,423
SurModics, Inc. and
Subsidiaries Condensed Consolidated Balance Sheets
(in thousands)
December 31,2015
September 30,2015
(Unaudited) Assets Cash and short-term investments $ 42,668 $
55,588 Restricted cash 786 ― Accounts receivable 5,522 7,478
Inventories 3,301 2,979 Other current assets 961
1,744 Total current assets 53,238 67,789 Property and
equipment, net 13,506 12,968 Intangible assets, net 16,502 2,760
Goodwill 21,822 8,010 Other assets 7,147 7,183 Total
assets $ 112,215 $ 98,710 Liabilities and Stockholders’
Equity Current liabilities $ 5,608 $ 4,700 Total current
liabilities 5,608 4,700 Contingent consideration 9,308 ―
Other liabilities 2,026 2,137 Total stockholders’ equity
95,273 91,873 Total liabilities and stockholders’ equity $
112,215 $ 98,710
SurModics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
Three Months EndedDecember
31,
2015 2014 (Unaudited) Operating Activities:
Net income $ 2,513 $ 3,614 Depreciation and amortization 909 683
Stock-based compensation 684 525
Contingent consideration accretion and
foreign currency transaction loss expenses
244 ― Deferred taxes 741 1,025 Net other operating activities (143
) (492 ) Change in operating assets and liabilities: Accounts
receivable 2,194 309 Accounts payable and accrued liabilities
(1,248 ) (508 ) Income taxes 508 413 Net change in other operating
assets and liabilities (274 ) (39 )
Net cash provided by operating activities
from continuing operations
6,128 5,530 Investing
Activities: Payments for acquisitions, net of cash acquired (18,156
) ― Net purchases of property and equipment (384 ) (41 ) Cash
transferred to discontinued operations ― (45 ) Net other investing
activities ― (2,238 ) Net cash used in investing activities
from continuing operations (18,540 ) (2,324 )
Financing Activities: Purchase of common stock to fund employee
taxes (353 ) (725 ) Repurchase of common stock ― (20,000 ) Net
other financing activities (155 ) 568 Net cash
used in financing activities from continuing operations (508
) (20,157 ) Net cash used in continuing operations
(12,920 ) (16,951 ) Discontinued operations: Net cash
used in operating activities ― (45 ) Net cash provided by financing
activities ― 45 Net cash provided by discontinued
operations ― ― Net change in cash and cash equivalents
(12,920 ) (16,951 ) Cash and Cash Equivalents: Beginning of period
55,588 43,511 End of period $ 42,668
$ 26,560
SurModics, Inc. and
Subsidiaries Supplemental Segment Information
(in thousands)
(Unaudited)
Three Months Ended December 31, 2015
2014 % Change Revenue % of Total
% of Total Medical Device $ 12,247 74.0 % $ 10,635
74.9 % 15.2 % In Vitro Diagnostics 4,294 26.0
3,570 25.1 20.3 Total revenue $ 16,541 100.0 % $ 14,205
100.0 % 16.4 %
Three Months Ended December 31,
2015 2014 Operating Income Medical
Device $ 3,830 $ 5,515 In Vitro Diagnostics 1,643 1,098 Corporate
(1,534 ) (1,579 ) Total operating income $ 3,939
$ 5,034
SurModics, Inc., and Subsidiaries Net Income and Diluted
EPS GAAP to Non-GAAP Reconciliation For the Three Months
Ended December 31, 2015
(in thousands, except per share data)
(Unaudited)
TotalRevenue
OperatingIncome
OperatingIncomePercentage
IncomeBeforeIncomeTaxes
NetIncome
DilutedEPS
GAAP $ 16,541 $ 3,939 23.8 % $ 3,805 $ 2,513 $ 0.19
Adjustments: Acquisition transaction, integration and other costs
(1) ― 2,531 15.3 2,531 2,225 0.17 Contingent consideration
accretion expense (2) ― 109 0.7 109 109 0.01 Research and
development tax credit (3) ― ― ― ― 135 (0.02 ) Foreign exchange
loss (4) ― ― ― 135 (222 ) 0.01 Amortization of intangible assets
(5) ― 354 2.1 354 298
0.02
Non-GAAP $ 16,541 $ 6,933 41.9 % $ 6,934 $ 5,058
$ 0.38 (1) Represents acquisition related
costs, including due diligence and integration expenses. Due
diligence and other fees include legal, tax, investment banker and
other expenses associated with acquisitions that can be highly
variable and not representative of on-going operations. (2) The
contingent consideration accretion adjustment represents accounting
adjustments to state contingent consideration liabilities at their
estimated fair value. (3) Represents the estimated discrete income
tax benefit associated with the December 2015 signing of the
Protecting Americans from Tax Hikes Act of 2015— which
retroactively reinstated federal R&D income tax credits for
calendar 2015. (4) Foreign exchange loss related to marking
contingent consideration to market. (5) To exclude amortization of
acquisition related intangible assets and associated tax impact.
SurModics, Inc., and Subsidiaries Net Income and
Diluted EPS GAAP to Non-GAAP Reconciliation For the Three
Months Ended December 31, 2014
(in thousands, except per share data)
(Unaudited)
TotalRevenue
OperatingIncome
OperatingIncomePercentage
IncomeBeforeIncomeTaxes
NetIncome
DilutedEPS
GAAP $ 14,205 $ 5,034 35.4 % $ 5,084 $ 3,614 $ 0.27
Adjustments: Research and development tax credit (1) ― ― ― ― (201 )
(0.02 ) Amortization of intangible assets (2) ― 151 1.1
151 96 0.01
Non-GAAP $ 14,205 $ 5,185 36.5 % $ 5,235 $ 3,509 $
0.26 (1) Represents a discrete income tax benefit
associated with the December 2014 signing of the Tax Increase
Prevention Act of 2014 which retroactively reinstated federal
R&D income tax credits for calendar 2014. (2) To exclude
amortization of acquisition related intangible assets and
associated tax impact.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160128005345/en/
SurModics, Inc.Andy LaFrence, 952-500-7000Vice President of
Finance and Chief Financial Officer
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024